BiotechTV - News - TopPodcast.com

Latest Episodes:

HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs Sep 16, 2026

Show notes

She highlights the company's next generation EGFR, which is in the clinic and reported early stage data at World Lung today, and she describes her goal with the company's Pan-KRAS inhibitor, which is still preclinical.

HCW 2026: As it approaches a BLA filing for its viral immunotherapy in prostate cancer, Candel has published its pivotal phase 3 data in Lancet Oncology and presented extended data at AUA Sep 16, 2026

Show notes

CEO Paul Peter Tak walks us through how the data has settled, and the steps the company needs to take before officially filing the BLA in Q4. Plus, an update on lung cancer.

HCW 2026: H.C. Wainwright & Co. Senior Biotech Analyst Andres Maldonado shares his take on the latest in oncology Sep 16, 2026

Show notes

He discusses the big year oncology has had, including in the RAS space, and highlights key catalysts he will be watching throughout the remainder of 2026.

HCW 2026: InflaRx designed izicopan from the start with the goal of having a differentiated, best in class profile vs the first marketed C5aR inhibitor. Now more than ever this could be opportune Sep 15, 2026

Show notes

Founder & CEO Niels Riedemann describes what he believes was lacking in design for the competitor, avacopan, which has been pulled from the market in many geographies and is currently in contention at FDA, and how izicopan was built to be different. Now InflaRx needs to prove this to investors and regulators of this.

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic." Sep 15, 2026

Show notes

Pascal Prigent describes the test, which can be used both do diagnose patients and to monitor them. On the therapeutics side, he also discusses IQIRVO, which is marketed by Ipsen, and GENFIT's R&D work in oncology and liver failure.

HCW 2026: Scribe Therapeutics, which represents the next generation of CRISPR, had its IPO in July - the first clinical program targets PCSK9 Sep 15, 2026

Show notes

Co-Founder and CEO Ben Oakes describes the difference between Scribe's approach and the first generation of CRISPR technologies. He then discusses the PCSK9 program, which harnesses epigenetic silencing, and preclinical work on Lp(a) and APOC3.

HCW 2026: With a $6B valuation, three approved products, up to $700M in revenue guidance this year, and a sizable acquisition under its belt, Mirum has become a rare disease leader Sep 15, 2026

Show notes

CEO Chris Peetz describes the vision for the company, and its acquisition of Bluejay, which will have phase three readouts both this quarter and next. Plus, his explanation of discussions with FDA on volixibat, and more phase 3 data that is scheduled this year on LIVMARLI.

HCW 2026: With an in-human proof of concept in hand from a rare condition, Prime Medicine is ready to go broader in new indications Sep 15, 2026

Show notes

CEO Allan Rein describes the proof of concept Prime has achieved with two patients in Chronic Granulomatous Disease, and discusses the companies plans in Wilson's Disease, Alpha-1 Antitrypsin Deficiency, and Cystic Fibrosis.

HCW 2026: H.C. Wainwright & Co.'s Managing Director of Healthcare Investment Banking James Cappuccio says that smaller biotech companies are now able to do large raises for the first time in a while Sep 15, 2026

Show notes

He discusses the financing dynamics of the biotech market currently, and comments on whether generalist investors are starting to participate in the sector again.

HCW 26: H.C. Wainwright Senior Biotechnology Analyst Mitchell Kapoor touches on current biotech sentiment, the cardiovascular space, in vivo CAR-T, and a pancreatic study to watch Sep 14, 2026

Show notes

Based on his analysis, a higher percentage of biotech companies have been trading up on positive data than the previous year. He also discusses going back to the drawing board on cardiovascular targets, in vivo CAR-T programs, and his key catatalysts to watch throughout the rest of the year.

Our TOPPODCAST Picks

Follow Us

Stay Connected

BiotechTV – News

Related Podcasts

Links

Stay Connected